UCI 趙 Chao Family Comprehensive Cancer Center



Thoracic Disease-Oriented Team

Clinical Research Treatment Flowchart

ALK Mutations

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

1L

UCI 24-192 (Nuvalent)
NVL-655 vs Alectinib

Mechanism: ALK inhibitor
Coord: Mindy Chen
PI: Dr. Nagasaka
Accrual: 3/5

2L

UCI 21-241 (Nuvalent)
NVL-655 + ALK inhibitor

Mechanism: ALK Inhibitor
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 20/25

UCI 25-51 (Nuvalent)
NVL-655 EAP

Mechanism: ALK inhibitor
Coord: Mindy Chen
PI: Dr. Park
Accrual: 25/30

UCI 25-189 (Astellas)

Mechanism: ALK inhibitor
Coord: Richard Chang
PI: Dr. Arter
Accrual: 4/5

UCI 26-23 (Triana Biomedicines)

Mechanism: ALK inhibitor
Coord: To be determined
PI: Dr. Nagasaka
Accrual: 0/10

UCI 26-38 (Chugai Pharmaceutical)
AQUA07 +/- Lorlatinib

Mechanism: ALK inhibitor
Coord: To be determined
PI: Dr. Nagasaka
Accrual: 0/5

EGFR Mutations

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

Exon 18

1L

UCI 24-169 (BlossomHill Therapeutics)
BH-30643 Capsule

Mechanism: EGFR or HER2 TKI
Coord: Celest Ramirez
PI: Dr. Nagasaka
Accrual: 14/15

Exon 19 del or L858R

1L

UCI 24-169 (BlossomHill Therapeutics)
BH-30643 Capsule

Mechanism: EGFR or HER2 TKI
Coord: Celest Ramirez
PI: Dr. Nagasaka
Accrual: 14/15

2L

UCI 23-178 (Systimmune)
BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody
Coord:Cassie Smith
PI: Dr. Park
Accrual: 7/10

UCI 25-187 (BMS/IZABRIGHT-Lung01)
Iza-Bren vs platinum based chemo + pemetrexed

Mechanism: ADC
Coord: Lizbeth Garcia
PI: Dr. Nagasaka
Accrual: 2/5

UCI 26-72 (HUTCHMED)
HMPL-A580

Mechanism: EGFR-directed antibody-targeted therapy conjugate (ATTC)
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

UCI 26-106 (UCLA L-14)
Teliso V + Osimertinib

Mechanism: ADC + TKI
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

EGFR Mutations

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

	Exon 20	Exon 21
1L	**24-169 (BlossomHill Therapeutics)** BH-30643 Capsule Mechanism: EGFR or HER2 TKI Coord: Celest Ramirez PI: Dr. Nagasaka Accrual: 14/15	**UCI 24-169 (BlossomHill Therapeutics)** BH-30643 Capsule Mechanism: EGFR or HER2 TKI Coord: Celest Ramirez PI: Dr. Nagasaka Accrual: 14/15
2L		

EARLY STAGE/RESECTABLE

Open to Accrual | Low Accruing | Pending Activation

Exon 20 / Uncommon and Compounded Mutations

1L

UCI 26-10 (UCLA/L-13)
Zipalertinib with Carboplatin + Pemetrexed

Mechanism: TKI + Chemo
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

UCI 26-175 (ArriVent/FURMO-006)
Firmonertinib vs Osimertinib or Afatinib

Mechanism: EGFR inhibitor
Coord: TBD
PI: Dr. Nagasaka
Accrual: 0/5

2L

HER2 MUTATIONS

ADVANCED/METASTATIC

	Overexpression	Exon 18	Exon 19	Exon 20	Exon 21
1L					
2L					

UCI 24-169 (BlossomHill Therapeutics)
BH-30643 Capsule

Mechanism: EGFR or HER2 TKI
Coord: Celest Ramirez
PI: Dr. Nagasaka
Accrual: 14/15

UCI 23-178
BL-B01D1 IV

Mechanism: EGFR and/or HER3 bispecific antibody
Coord: Cassie Smith
PI: Dr. Park
Accrual: 7/10

HER2 Mutations

Early Stage

Open to Accrual | Low Accruing | Pending Activation

UCI 25-79 (Beamion Lung-3)
Zongertinib vs SOC
(Adjuvant therapy)

Mechanism: TKI
Coord: Stephanie Fernandez
PI: Dr. Arter
Accrual: 0/3

KRAS MUTATIONS

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

KRAS G12C

1L

UCI 22-30 (D3S-001-100): D3 Bio

Mechanism: TKI
Coord: Cassie Smith
PI: Dr. Nagasaka
Accrual: 5/8

UCI 25-88 (Part A: Olomorasib w/ Pembro or Placebo w/ Pembro. **Part B:** Durvalumab w/ Pembro or Placebo w/ Durvalumab)

Mechanism: TKI and Anti-PD-1 / Anti-PD-L1
Coord: Lizbeth Garcia
PI: Dr. Park
Accrual: 0/5

UCI 25-164: Divarasib + Pembro vs Pembro + Pem + Carbo or Cisplatin

Mechanism: TKI+IO+Chemo
Coord: Lizbeth Garcia
PI: Dr. Nagasaka
Accrual: 0/5

2L

UCI 23-116 (RMC-6291 Revolution Medicine)

Mechanism: TKI
Coordinator: Richard Chang
PI: Dr. Arter
Accrual: 3/10

UCI 25-162: BBO-8520(The ONKORAS-101

Mechanism: TKI
Coord: Mindy Chen
PI: Dr. Arter
Accrual: 0/5

G12A, G12D, G12R, G12S, G12V (Cont.)

UCI 22-87 (RMC-6236 Revolution Med)

Mechanism: TKI
Coordinator: Jenny Choe
PI: Dr. Arter
Accrual: 43/50

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

G12C, G12V, G12D

1L

2L

UCI 25-163 (TBBO11818-101)
NSCLC cohorts closed

Mechanism: TKI
Coord: Cassie/Keagan
PI: Dr. Arter
Accrual: 0/5

UCI 26-176 (HUTCHMED/HMPL-A830)

Mechanism: Pan-KRAS ADC
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

NTRK Mutations

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

NTRK 1-3

1L

2L

TP53 Mutations

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

ROS1 Mutations

ADVANCED/METASTATIC

Open to Accrual | Low Accruing | Pending Activation

ROS1

1L

2L

UCI 21-47 (NVL-520 Nuvalent)

Mechanism: TKI
Coord: Keagan Buttigieg
PI: Dr. Nagasaka
Accrual: 12/16

ROS1 Mutations

Early Stage

Open to Accrual | Low Accruing | Pending Activation

UCI 24-196 (Nuvation)
Taletrectinib vs Placebo post complete resection
(Adjuvant therapy)

Mechanism: ROS1 inhibitor
Coord: Stephanie Fernandez
PI: Dr. Arter
Accrual: 0/5

Advanced / Metastatic

Open to Accrual | Low Accruing | Pending Activation

1L

UCI 24-83: CB-NK + Atezolizumab

Mechanism: PD-L1
Coord: TBD
PI: Dr. Villalona
Accrual: 0/9

UCI 25-114: Ivonescimab vs Pembrolizumab (High PD-L1 Expression (TPS> 50%)

Mechanism: PD-L1
Coord: Richard Chang
PI: Dr. Park
Accrual: 0/5

UCI 24-195 (Seagen/Pfizer): PF-08046054/SGN-PDL1V
NSCLC cohorts closed

Mechanism: PD-L1
Coord: Jenny Choe
PI: Dr. Nagasaka
Accrual: 0/5

2L

UCI 25-101 UCLA/Summit Therapeutics: Thymic Cancer (Ivonescimab)

Mechanism: PD-L1
Coord: Cassie Smith
PI: Dr. Arter
Accrual: 0/5

Mechanism: PD-L1
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

Open to Accrual Low Accruing Pending Activation

MTAP Mutations

UCI 24-197 (TNG456 Monotherapy & Combo w/ Abemaciclib)

Mechanism:
Coord: Cassie Smith
PI: Dr. Park
Accrual: 1/5

Open to Accrual Low Accruing Pending Activation

DLL3 Mutations

UCI 25-133: (ZG006)

Mechanism: BiTE molecule
Coord: Jenny Choe
PI: Dr. Arter
Accrual: 2/5

Open to Accrual Low Accruing Pending Activation

SMARCA4 Mutations

UCI 25-194 (Plexium)
PLX-61639

Mechanism: SMARCA2 Degrader
Coord: Jenny Choe
PI: Dr. Villalona
Accrual: 0/5

NON-Mutationally Driven Trials

Open to Accrual | Low Accruing | Pending Activation

Adjuvant

ADVANCED/METASTATIC

Non-Treatment Studies

Open to Accrual | Low Accruing | Pending Activation

UCI 22-86: Gut Microbiome Study

Mechanism: Fecal Collection
Coord: Stephanie Fernandez
PI: Dr. Nagasaka
Accrual: 16/82

UCI 24-118 (Keshava IIT): Lung Cancer Family Screening

Mechanism: NA
Coord: Stephanie Fernandez/ Mindy Chen
PI: Dr. Keshava
Accrual: 69/1753

UCI 25-179 (T. Waddington IIT)
Optical Coherence Tomography (OCT) w/ Robotic assisted bronch evaluate peripheral nodes

Mechanism: N/A
CRC: TBD
PI: Dr. Waddington
Accrual: 0/10

UCI 25-191 (Nagasaka IIT)
Mechanism: N/A
CRC: TBD
PI: Dr. Nagasaka
Accrual: 0/25

UCI 24-87 (Arter IIT): Methionine-Reduced Diet

Mechanism: N/A
CRC: Keagan Buttigieg
PI: Dr. Arter
Accrual: 7/25

UCI 23-155:
Chatbot for Online Support Groups to Treat Tobacco Addiction

Mechanism: N/A
CRC: TBD
PI: Dr. Pechmann
Accrual: 0/126

UCI 26-126 (Sadigh IIT):
Empowering Pts Lung Ca Screening Uptake: Empower LCS Call

Mechanism: NA
Coord: NA
PI: Dr. Sadigh
Accrual: 3/80

Open to Accrual | Low Accruing | Pending Activation

Basket Trials

Advanced / Metastatic

1L

UCI 24-113 (BMS-986482)
Bristol-Myers Squibb

Mechanism: PDL1
Coord: Natalie Arechiga
PI: Dr. Chow
Accrual: 5/10

2L

UCI 24-08 (SPEDOX-6): Dr. Chow IIT

Mechanism: SPE
Coord: Erin Palmer-Torrison
PI: Dr. Chow
Accrual: 9/67

UCI 25-163 (TBBO11818-101)
NSCLC cohorts closed

Mechanism: TKI
Coord: Cassie/Keagan
PI: Dr. Arter
Accrual: 0/5

UCI 26-118 (YL211-INT-101-01)
Y211 +/- Pembro

Mechanism: c-MET targeting ADC
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

UCI 26-176 (HUTCHMED/HMPL-A830)

Mechanism: Pan-KRAS ADC
Coord: TBD
PI: Dr. Arter
Accrual: 0/5

Open to Accrual | Low Accruing | Pending Activation

LUNGMAP:
Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer

Mechanism: N/A
CRC: TBD
PI: Dr. Arter
Accrual: 0/10

SWOG-S1900N:
Sacituzumab Govitecan Alone, Ivonescimab Alone, or Sacituzumab Govitecan and Ivonescimab for patients w/ stage IV NSCLC previously-treated driver mutation

Mechanism: IO
CRC: TBD
PI: Dr. Park
Accrual: 0/5